| Autor: |
Tove T Borgen, Lene B Solberg, Trine Lauritzen, Ellen M Apalset, Åshild Bjørnerem, Erik F Eriksen |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
JBMR Plus, Vol 6, Iss 6, Pp n/a-n/a (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2473-4039 |
| DOI: |
10.1002/jbm4.10633 |
| Popis: |
ABSTRACT The serum bone turnover markers (BTM) procollagen type 1 N‐terminal propeptide (P1NP) and C‐terminal cross‐linking telopeptide of type 1 collagen (CTX) are recommended for monitoring adherence and response of antiresorptive drugs (ARD). BTM are elevated about 1 year after fracture and therefore BTM target values are most convenient in ARD treatment follow‐up of fracture patients. In this prospective cohort study, we explored the cut‐off values of P1NP and CTX showing the best discriminating ability with respect to adherence and treatment effects, reflected in bone mineral density (BMD) changes. Furthermore, we explored the ability of BTM to predict subsequent fractures and BTM variation during daytime in patients using ARD or not. After a fragility fracture, 228 consenting patients (82.2% women) were evaluated for ARD indication and followed for a mean of 4.6 years (SD 0.5 years). BMD was measured at baseline and after 2 years. Serum BTM were measured after 1 or 2 years. The largest area under the curve (AUC) for discrimination of patients taking ARD or not was shown for P1NP 2% gain in BMD (lumbar spine and total hip) was largest at cut‐off values for P1NP |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text